Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 study study of Celecoxib/ciprofloxacin

Trial Profile

A phase 3 study study of Celecoxib/ciprofloxacin

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 30 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 24 Apr 2025 According to a NeuroSense Therapeutics media release, the company releases letter to shareholders outlining Phase 3 timeline for PrimeC in ALS
  • 11 Dec 2024 According to a NeuroSense Therapeutics media release, company plans to submit a final protocol to the FDA during the first half of 2025 with the aim of commencing enrollment of the pivotal Phase 3 study in mid-2025.
  • 11 Dec 2024 According to a NeuroSense Therapeutics media release, company announced it has concluded a Type C meeting with the U.S. FDA for PrimeC in the treatment of amyotrophic lateral sclerosis (ALS). The purpose of the meeting was to discuss the design of a proposed Phase 3 clinical study and the plan for submission of an eventual 505(b)(2) marketing application. The Company also discussed efficacy and safety measurements regarding planned Phase 3 pivotal study with PrimeC.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top